Indivior Pharmaceuticals (INDV) Accounts Payables (2021 - 2026)

Indivior Pharmaceuticals has reported Accounts Payables for 6 years, with the latest figure at $206.0 million in Q2 2026.

• On a quarterly basis, Accounts Payables rose 5.1% year-over-year to $206.0 million in Q2 2026; TTM through Jun 2026 was $206.0 million, a 5.1% increase from a year earlier, with the FY2025 full-year figure at $250.0 million, up 15.74% from the prior year.
• Accounts Payables was $206.0 million for Q2 2026 at Indivior Pharmaceuticals, up from $178.0 million in the prior quarter.
• The five-year high for Accounts Payables was $617.0 million in Q4 2022, with the low at $178.0 million in Q1 2026.
• Average Accounts Payables over 5 years is $250.7 million, with a median of $206.0 million recorded in 2026.
• The sharpest annual moves came in 2023 and 2025: Accounts Payables plunged 68.4% in 2023, then climbed 15.74% in 2025.
• Over 5 years, Accounts Payables stood at $617.0 million in 2022, then slumped by 68.4% to $195.0 million in 2023, then gained by 10.77% to $216.0 million in 2024, then advanced by 15.74% to $250.0 million in 2025, then dropped by 17.6% to $206.0 million in 2026.
• The last three Accounts Payables figures came in at $206.0 million (Q2 2026), $178.0 million (Q1 2026), and $250.0 million (Q4 2025), per Business Quant data.